Cantor Fitzgerald initiated coverage of Opus Genetics (IRD) with an Overweight rating and $15 price target Clinical data in inherited eye diseases, LCA5 and bestrophinopathies, caused by BEST1 mutations is “much more impressive” than Luxturna in LCA2, the analyst tells investors in a research note. Three-month data in BEST1 expected in mid-2026 is a major potential catalyst, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics initiated with an Overweight at Cantor Fitzgerald
- Oppenheimer bullish on Opus Genetics, initiates with an Outperform
- Opus Genetics initiated with an Outperform at Oppenheimer
- Opus Genetics files to sell 7.37M shares of common stock for holders
- Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst